XXII - 22nd Century Group, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.2800
-0.0700 (-2.98%)
At close: 3:59PM EDT

2.2700 -0.03 (-1.09%)
After hours: 6:59PM EDT

Stock chart is not supported by your current browser
Previous Close2.3500
Open2.3200
Bid2.2900 x 1800
Ask2.3000 x 45900
Day's Range2.2500 - 2.3400
52 Week Range1.1200 - 3.2900
Volume749,693
Avg. Volume1,249,460
Market Cap286.514M
Beta (3Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

    22nd Century Group Files 2019 Second Quarter Report

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine Content tobacco and hemp/cannabis research, announced today that the Company filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 with the U.S. Securities and Exchange Commission. The Company will provide a business update for investors on a conference call to be held on Thursday, August 8, 2019, at 4:00 PM (Eastern Time). Clifford B. Fleet, President and Chief Executive Officer of 22nd Century Group, together with John T. Brodfuehrer, Chief Financial Officer, will conduct the call.

  • Business Wire

    22nd Century Group Appoints Cliff Fleet Chief Executive Officer

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis plant research, announced today that the Company has appointed Clifford B. Fleet to serve as the Company’s President and CEO, effective August 3, 2019. Mr. Fleet has also been elected to serve as a member of the Company’s Board of Directors. Mr. Fleet has served as a strategic advisor to 22nd Century Group since December 2018.

  • Business Wire

    22nd Century Group Announces Conference Call to Provide Business Update

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis plant research, announced today that the Company will provide a business update for investors on a conference call to be held Thursday, August 8, 2019, at 4:00 PM (Eastern Time). Michael Zercher, Chief Operating Officer of 22nd Century Group, together with John T. Brodfuehrer, Chief Financial Officer, will conduct the call. The conference call will consist of an overview of recent business highlights and a review of the Company's second quarter 2019 financial results.

  • ACCESSWIRE

    The LD Micro Index Turns Four Years Old

    LOS ANGELES, CA / ACCESSWIRE / August 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted (again) as of August 1, 2019. LD Micro has always held the belief that our ...

  • Business Wire

    22nd Century Group Appoints Michael J. Zercher as Chief Operating Officer

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis research, announced today the appointment of Michael J. Zercher as the Company’s Chief Operating Officer. “Since joining 22nd Century in 2016, Mike has become a highly valued member of our team providing critical leadership in several areas of our business. James W. Cornell, Director & Chairman of the Board of 22nd Century Group added, “Mike will drive our efforts to successfully bring 22nd Century’s proprietary VLNC cigarettes to market in the U.S. and internationally, as well as lead our Company’s strategic expansion in the hemp/cannabis space.

  • Business Wire

    22nd Century Files 2019 First Quarter Report and Announces Conference Call to Provide Business Update

    22nd Century’s proposed VLN™ cigarettes continue to fall squarely within the nicotine range that public health officials anticipate will be mandated by the FDA. 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today that the Company filed its 2019 First Quarter Report on Form 10-Q with the U.S. Securities and Exchange Commission. The Company will provide a business update for investors on a conference call to be held Wednesday, May 8, 2019, at 4:00 PM (Eastern Time).

  • Business Wire

    22nd Century’s Pre-Market Tobacco Application for VLN™ Cigarettes Advances with Completed FDA Inspection

    22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is a world leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today that last week the U.S. Food and Drug Administration (FDA) conducted a comprehensive inspection of the Company’s manufacturing facility in North Carolina as a part of the FDA’s review of 22nd Century’s Pre-Market Tobacco (PMT) application for the Company’s VLN™ cigarettes. 22nd Century’s proposed VLN™ cigarettes are made with the Company’s proprietary Very Low Nicotine Content (VLNC) tobacco.

  • Business Wire

    Grossly Misleading “Short and Distort” Article Wrongfully Attempts to Dupe 22nd Century Group Shareholders

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a world leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, today commented on a grossly misleading article published yesterday by an anonymous self-professed short seller of the Company’s stock. Publishing under the pen name “Fuzzy Panda,” the author – who will not even identify who he is – continued his baseless smear campaign against the Company in an effort to depress the share price of 22nd Century stock and to make a personal profit by duping shareholders into selling their shares. Although 22nd Century does not normally respond to “short and distort” articles or to “hit pieces,” the Company believes the grossly misleading mischaracterizations and wrongful innuendo contained in the subject article warranted a Company response.

  • Business Wire

    22nd Century Group Hires Former Imperial Brands Head of Regulatory Science

    22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today the hiring of John D. Pritchard as Vice President of Regulatory Science. Mr. Pritchard was formerly the Head of Regulatory Science for Imperial Brands, U.K. (LSE:IMB).

  • ACCESSWIRE

    Cannabis Stocks to Watch

    HENDERSON NV / ACCESSWIRE / April 11, 2019 / With the market off to its best first quarter over the past 2 decades and the cannabis industry being one of the hottest in the market, now is an ideal time ...

  • Business Wire

    22nd Century Announces Exclusive Worldwide Agreement with KeyGene for Genetic Development of Hemp/Cannabis

    Strategic collaboration will bolster 22nd Century’s position as a global leader in hemp/cannabis genetics. 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today that the Company has entered into a worldwide strategic research and development agreement with KeyGene, www.keygene.com, a global leader in plant research involving high-value genetic traits and increased crop yields. This exclusive, worldwide collaboration will focus on developing hemp/cannabis plants with exceptional cannabinoid profiles for medical and therapeutic use among other applications.

  • Business Wire

    22nd Century Group Issues Annual Letter to Shareholders

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today that the Company has issued its annual letter to shareholders as part of 22nd Century Group’s 2018 Annual Report. The 2018 letter to shareholders is reprinted below.

  • Business Wire

    22nd Century’s New Study Confirms Very Low Nicotine Content Cigarettes Result in 97% Less Nicotine in Smoker’s Bloodstream

    22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is focused on tobacco harm reduction and hemp/cannabis research, announced today the results of a recently completed, company-sponsored study involving 22nd Century’s Very Low Nicotine Content (VLNC) cigarettes. The results indicate that subjects using the VLNC product had 97% less nicotine in their blood as compared to their blood-nicotine levels after use of their usual brand of highly addictive commercial cigarettes. 22nd Century’s important new study was included in the Company’s Modified Risk Tobacco Product (MRTP) application, which was previously submitted to the U.S. Food and Drug Administration (FDA) for 22nd Century’s VLNC cigarettes under the proposed brand name VLN™.

  • PR Newswire

    Lifshitz & Miller LLP Announces Investigation of 22nd Century Group, Activision Blizzard, Inc., Astec Industries, Inc., Avon Products, Inc., Axogen, Inc., Everquote Inc. and Health Insurance Innovations, Inc.

    NEW YORK , March 22, 2019 /PRNewswire/ -- 22 nd  Century Group (XXII) Lifshitz & Miller  announces investigation into possible securities laws violations in connection with allegations that  XXII's stock ...

  • ACCESSWIRE

    22nd Century Group, Inc. (XXII), Arlo Technologies, Inc. (ARLO), Micron Technology, Inc. (MU) Class Action Reminder Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / March 22, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review ...

  • GlobeNewswire

    Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against 22nd Century Group, Inc. (XXII)

    Glancy Prongay & Murray LLP (“GPM”) reminds investors of the March 22, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased 22nd Century Group, Inc.  (“22nd Century” or the “Company”) (NYSE American: XXII) securities between February 18, 2016 and October 25, 2018, inclusive (the “Class Period”). 22nd Century investors have until March 22, 2019 to file a lead plaintiff motion.

  • GlobeNewswire

    DEADLINE FRIDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against 22nd Century Group, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

    LOS ANGELES, March 21, 2019 -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against 22nd Century Group,.

  • GlobeNewswire

    Pawar Law Group Announces a Securities Class Action Lawsuit Against 22nd Century Group, Inc. – XXII 

    Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of 22nd Century Group, Inc. (XXII) from February 18, 2016 through October 25, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for 22nd Century Group investors under the federal securities laws.  If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2019. To join the 22nd Century Group class action, go to http://pawarlawgroup.com/cases/22nd-century-group-inc/ or call Vik Pawar, Esq.

  • GlobeNewswire

    22nd Century Group, Inc. (XXII), Arlo Technologies, Inc. (ARLO), Micron Technology, Inc. (MU) Bronstein, Gewirtz & Grossman, LLC Class Action Reminder

    NEW YORK, March 20, 2019 -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following.

  • ACCESSWIRE

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in 22nd Century Group, Inc. of Class Action Lawsuit and Upcoming Deadline – XXII

    NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against 22nd Century Group, Inc. (''22nd Century'' or the ''Company'') (NYSE American: XXII) and certain of its officers and directors. The class action, filed in United States District Court, Eastern District of New York, and indexed under 19-cv-00553, is on behalf of a class consisting of all behalf of persons and/or entities who purchased or otherwise acquired 22nd Century securities between February 18, 2016 through October 25, 2018, both dates inclusive (the ''Class Period''), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

  • ACCESSWIRE

    ATVI, XXII, ARLO – CLASS ACTION - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...

  • GlobeNewswire

    Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against 22nd Century Group, Inc. (XXII)

    Law Offices of Howard G. Smith reminds investors of the March 22, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased 22nd Century Group, Inc. (“22nd Century” or the “Company”) (NYSE American: XXII) securities between February 18, 2016 and October 25, 2018, inclusive (the “Class Period”). 22nd Century investors have until March 22, 2019 to file a lead plaintiff motion. Investors suffering losses on their 22nd Century investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.